Chang Yu Wang

Array ( [id] => 19462436 [patent_doc_number] => 20240316105 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-26 [patent_title] => NOVEL CHIMERIC RECEPTOR COMPOSITION, RECOMBINANT VECTOR, CELL, AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 18/578264 [patent_app_country] => US [patent_app_date] => 2022-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6842 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18578264 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18020595 [patent_doc_number] => 20220372094 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-24 [patent_title] => Use of erythropoietin-derived peptide through effect on cell damage prevention thereof [patent_app_type] => utility [patent_app_number] => 17/811174 [patent_app_country] => US [patent_app_date] => 2022-07-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5964 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17811174 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19465526 [patent_doc_number] => 20240319196 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-26 [patent_title] => METHODS FOR PREDICTING MULTI-ORGAN METASTATIC DISEASE AND OVERALL AND PROGRESSION FREE SURVIVAL IN SUBJECTS HAVING HYPER-ENGORGED CIRCULATING CANCER ASSOCIATED MACROPHAGE-LIKE CELLS (CAMLS) [patent_app_type] => utility [patent_app_number] => 18/576514 [patent_app_country] => US [patent_app_date] => 2022-07-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6658 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18576514 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17945791 [patent_doc_number] => 20220332808 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-20 [patent_title] => HUMAN-DERIVED ANTI-HUNTINGTIN (HTT) ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/810113 [patent_app_country] => US [patent_app_date] => 2022-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54364 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17810113 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18182559 [patent_doc_number] => 20230043289 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-09 [patent_title] => ANTI-TAU ANTIBODIES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/846302 [patent_app_country] => US [patent_app_date] => 2022-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39337 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17846302 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18626550 [patent_doc_number] => 20230285338 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2023-09-14 [patent_title] => METHODS FOR TREATING MICROGLIAL DYSFUNCTION [patent_app_type] => utility [patent_app_number] => 17/840368 [patent_app_country] => US [patent_app_date] => 2022-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32322 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17840368 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18626550 [patent_doc_number] => 20230285338 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2023-09-14 [patent_title] => METHODS FOR TREATING MICROGLIAL DYSFUNCTION [patent_app_type] => utility [patent_app_number] => 17/840368 [patent_app_country] => US [patent_app_date] => 2022-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32322 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17840368 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19387937 [patent_doc_number] => 20240277807 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-22 [patent_title] => ACTRII PROTEINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/568140 [patent_app_country] => US [patent_app_date] => 2022-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 67276 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -56 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18568140 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19418510 [patent_doc_number] => 20240294633 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-05 [patent_title] => ANTIBODY SPECIFIC FOR ANTI-BCL-6 ANTIBODY AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/566522 [patent_app_country] => US [patent_app_date] => 2022-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35853 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18566522 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19343576 [patent_doc_number] => 20240252539 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-01 [patent_title] => CHIMERIC ANTIGEN RECEPTOR TO TARGET HLA-G-POSITIVE CANCERS [patent_app_type] => utility [patent_app_number] => 18/560791 [patent_app_country] => US [patent_app_date] => 2022-05-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30488 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -104 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18560791 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19464485 [patent_doc_number] => 20240318154 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-26 [patent_title] => GENE THERAPY FOR THE TREATMENT OF SEVERE COMBINED IMMUNODEFICIENCY (SCID) RELATED TO RAG1 [patent_app_type] => utility [patent_app_number] => 18/561938 [patent_app_country] => US [patent_app_date] => 2022-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16134 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18561938 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19359341 [patent_doc_number] => 20240261375 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-08 [patent_title] => PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING DISORDER ASSOCIATED WITH ADMINISTRATION OF ANTICANCER AGENT [patent_app_type] => utility [patent_app_number] => 18/560442 [patent_app_country] => US [patent_app_date] => 2022-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11994 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18560442 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17851933 [patent_doc_number] => 20220281975 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-08 [patent_title] => TREM2 ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/737439 [patent_app_country] => US [patent_app_date] => 2022-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4968 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 116 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17737439 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20527301 [patent_doc_number] => 12545725 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-02-10 [patent_title] => Anti-PACAP antibodies, nucleic acids and methods of making thereof [patent_app_type] => utility [patent_app_number] => 17/723674 [patent_app_country] => US [patent_app_date] => 2022-04-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 79 [patent_figures_cnt] => 246 [patent_no_of_words] => 68885 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 133 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17723674 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17958619 [patent_doc_number] => 20220339199 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-27 [patent_title] => PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING RETINAL DEGENERATIVE DISEASE, COMPRISING HUMAN NEURAL CREST-DERIVED NASAL INFERIOR TURBINATE STEM CELLS AS ACTIVE INGREDIENT [patent_app_type] => utility [patent_app_number] => 17/659348 [patent_app_country] => US [patent_app_date] => 2022-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6825 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17659348 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18207844 [patent_doc_number] => 20230054101 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-23 [patent_title] => TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS [patent_app_type] => utility [patent_app_number] => 17/721715 [patent_app_country] => US [patent_app_date] => 2022-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15498 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17721715 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17960269 [patent_doc_number] => 20220340849 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-27 [patent_title] => BRAIN-CHIP MODELING NEURODEGENERATION AND NEUROINFLAMMATION IN PARKINSON'S DISEASE [patent_app_type] => utility [patent_app_number] => 17/719627 [patent_app_country] => US [patent_app_date] => 2022-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51630 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17719627 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17748101 [patent_doc_number] => 20220226304 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-21 [patent_title] => Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase [patent_app_type] => utility [patent_app_number] => 17/700804 [patent_app_country] => US [patent_app_date] => 2022-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31384 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17700804 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17734713 [patent_doc_number] => 20220220172 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-14 [patent_title] => PROGRANULIN VARIANTS [patent_app_type] => utility [patent_app_number] => 17/698456 [patent_app_country] => US [patent_app_date] => 2022-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42902 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17698456 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17930113 [patent_doc_number] => 20220325238 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-13 [patent_title] => WNT COMPOSITIONS AND METHODS FOR SERUM-FREE SYNTHESIS [patent_app_type] => utility [patent_app_number] => 17/698636 [patent_app_country] => US [patent_app_date] => 2022-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25062 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17698636 [rel_patent_id] =>[rel_patent_doc_number] =>)